Research Analysts Offer Predictions for GSK FY2027 Earnings

GSK plc (NYSE:GSK) – Research analysts at Zacks Research increased their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March 25th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings per share of $5.05 for the year, up from their previous forecast of $5.04. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

Several other equities research analysts have also weighed in on GSK. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

NYSE:GSK opened at $38.54 on Thursday. The company has a fifty day moving average price of $37.11 and a 200 day moving average price of $36.82. GSK has a one year low of $31.72 and a one year high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a market cap of $79.77 billion, a P/E ratio of 24.24, a PEG ratio of 1.12 and a beta of 0.58.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GSK. Dodge & Cox increased its position in shares of GSK by 0.5% during the fourth quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock worth $2,314,672,000 after acquiring an additional 353,749 shares in the last quarter. FMR LLC increased its holdings in GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA increased its holdings in GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after purchasing an additional 10,407,905 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after purchasing an additional 259,867 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of GSK by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company’s stock valued at $255,914,000 after purchasing an additional 35,134 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.08%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.